Fosrenol approved in predialysis patients

Patients with chronic kidney disease and hyperphosphataemia can now be treated with Fosrenol (lanthanum carbonate) even if they have not yet started dialysis.

Alongside Alu-Cap (aluminium hydroxide) and Phosex (calcium acetate), Fosrenol is the third phosphate binder to be licensed for predialysis use.

The drug, which comes as chewable tablets, can be used in this setting when a low-phosphate diet fails to reduce serum phosphate levels below 1.78mmol/l. As lanthanum is mainly excreted in bile, monitoring of liver function is recommended.

View Fosrenol drug record

Further information: Shire

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases